Home / Market News / $UTHR
benzinga Corporate Catalyst Impact 55/100 ● positive

JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $687

Jul 23, 2026, 6:47 PM UTC · Primary ticker $UTHR

JP Morgan analyst Jessica Fye reiterated an Overweight rating on United Therapeutics and slightly increased its price target from $685 to $687. This indicates a continued positive outlook from the analyst, though the modest price target adjustment suggests a limited immediate market impact.

JP Morgan analyst Jessica Fye maintained an 'Overweight' rating on United Therapeutics (UTHR) and slightly raised the price target from $685 to $687. This action signals continued confidence in the company's prospects from a prominent investment bank. While the price target increase is minor, it reinforces a positive sentiment for UTHR, potentially providing a small boost to investor confidence. For traders, this is a moderately positive signal, suggesting stability and a favorable outlook, but unlikely to cause a significant short-term price surge given the small adjustment. Long-term implications are more about sustained analyst support rather than a new catalyst.

$UTHR positive Price target raised, Overweight rating maintained
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.